Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma
Matthew Hellmann1, Naiyer Rizvi2, Jedd D Wolchok1
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
Abstract:
The recent successes of immune checkpoint therapies have established a new era for the treatment of patients with cancer, yet the predictors of response remain largely undetermined. We recently demonstrated that the genomic landscape of lung cancers substantially influences the response to programmed cell death 1 receptor (PD-1) blockade, providing new insights into the molecular determinants of the response to immunotherapy.
Insights
Predicting cancer immunotherapy response is key. Lung cancer’s genomic landscape significantly impacts how patients respond to programmed cell death 1 receptor (PD-1) blockade, offering new insights into immunotherapy effectiveness.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Immune checkpoint inhibitors, particularly programmed cell death 1 receptor (PD-1) blockade, represent a significant advancement in cancer treatment.
- However, identifying reliable predictors of patient response to these therapies remains a critical challenge in clinical oncology.
Purpose of the Study:
- To investigate the influence of the genomic landscape of lung cancers on the response to PD-1 blockade therapy.
- To uncover molecular determinants that dictate patient response to cancer immunotherapy.
Main Methods:
- Analysis of the genomic profiles of lung cancer tumors.
- Correlation of genomic features with clinical response data to PD-1 blockade.
Main Results:
- The genomic landscape of lung cancers was found to substantially influence response to PD-1 blockade.
- Specific genomic alterations were associated with differential treatment outcomes, highlighting key molecular determinants.
Conclusions:
- Genomic profiling of lung cancers provides crucial insights into predicting response to PD-1 blockade.
- Understanding the genomic determinants of response can guide the development of more effective cancer immunotherapies.
